Please ensure Javascript is enabled for purposes of website accessibility

The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today

By Brian Feroldi – Nov 2, 2018 at 10:37AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares fall hard after the company reports good news. What's going on?

What happened

After the company reported third-quarter results, shares of Adamas Pharmaceuticals (ADMS), a commercial-stage biopharma focused on chronic neurological disorders, fell 23% as of 11:20 a.m. EDT on Friday. 

So what

Here's a look at the key numbers from the third quarter:

  • Revenue from sales of the Parkinson's disease drug Gocovri were $10.6 million during the quarter. That topped Wall Street's estimate of $10.1 million.
  • Net loss per share was $33.2 million, or $1.22 per share. That was higher than the year-ago period, but it was lower than the $1.34 loss that market watchers were expecting.
  • Cash balance at quarter end was $233.2 million.
Coins slipping through a man's fingers.

Image source: Getty Images.

In a separate news item, Adamas' shares were given a "buy" rating by Cowen today, and a price target of $30 has been set.

So if the results were strong and the company received a "buy" rating, why are shares down today? The answer to that question isn't clear at this time, but it is possible that investors still don't know how much the FDA approval of Osmotica Pharmaceuticals and Vertical Pharmaceuticals' drug Osmolex will impact Gocovri's sales in the long run. That concern has been weighing on the share price all year, so it's possible that today's price action is just a continuation of that narrative.

Another potential nitpick from Wall Street might be that the rate of new prescribers isn't as robust as expected When pressed on this issue on the call with investors, management stated that they were deliberately targeting a greater penetration rate within the highest-volume offices.

Either way, the net result is that shareholders are having another tough day.

Now what

Given the upbeat sales results and falling share price, today is likely to be a frustrating day for Adamas' bulls.

On the call with investors, management said that it remained "confident" in its ongoing patent enforcement action against Osmotica. However, the company didn't have any news to share with investors at this time. 

There's not much that Adamas' bulls can do about today's share price action beyond waiting for the sentiment to turn. That should happen eventually if Gocovri sales continue to grow and the potential threat from Osmotica proves to be overblown.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Adamas Pharmaceuticals, Inc. Stock Quote
Adamas Pharmaceuticals, Inc.
ADMS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.